Table of Contents Table of Contents
Previous Page  4 / 52 Next Page
Show Menu
Previous Page 4 / 52 Next Page
Page Background


FDA Grants Nivolumab Breakthrough Designation for Head and Neck Cancer

Published Online:

Monday, Apr 25, 2016

The FDA has granted a breakthrough therapy designation to nivolumab

(Opdivo) as a treatment for patients with recurrent or metastatic squamous cell

carcinoma of the head and neck (SCCHN) following a platinum-based therapy,

according to the developer of the PD-1 inhibitor Bristol-Myers Squibb

The FDA is expected to act on the review by Nov. 11, 2016, according to a

written statement

from Bristol-Myers Squib, makers of nivolumab.

19 Apr 2016